Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Cost of Revenue (2016 - 2018)

Historic Cost of Revenue for Theravance Biopharma (TBPH) over the last 5 years, with Q1 2018 value amounting to $826000.0.

  • Theravance Biopharma's Cost of Revenue rose 4619.47% to $826000.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $6.3 million, marking a year-over-year increase of 13465.12%. This contributed to the annual value of $6.0 million for FY2017, which is 10836.21% up from last year.
  • Latest data reveals that Theravance Biopharma reported Cost of Revenue of $826000.0 as of Q1 2018, which was up 4619.47% from $3.1 million recorded in Q4 2017.
  • Over the past 5 years, Theravance Biopharma's Cost of Revenue peaked at $3.2 million during Q4 2014, and registered a low of $188000.0 during Q1 2014.
  • Moreover, its 5-year median value for Cost of Revenue was $638000.0 (2016), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Theravance Biopharma's Cost of Revenue crashed by 6419.87% in 2016, and later surged by 19668.67% in 2017.
  • Quarter analysis of 5 years shows Theravance Biopharma's Cost of Revenue stood at $3.2 million in 2014, then decreased by 0.65% to $3.2 million in 2015, then crashed by 64.2% to $1.1 million in 2016, then soared by 171.9% to $3.1 million in 2017, then plummeted by 73.49% to $826000.0 in 2018.
  • Its last three reported values are $826000.0 in Q1 2018, $3.1 million for Q4 2017, and $985000.0 during Q3 2017.